Scleroderma News highlighted a study that found that lenabasum, a potential treatment of diffuse cutaneous scleroderma, was shown to be safe, well-tolerated and beneficial for patients.

HSS rheumatologist Robert F. Spiera, MD, the trial's principal investigator, will present research findings at the European League Against Rheumatism (EULAR) 2018 Annual Meeting in Amsterdam.

Data collected from 25 patients showed an improvement of 56 percent on their ACR CRISS (American College of Rheumatology's diffuse cutaneous systemic sclerosis) score after completing 52 weeks of lenabasum treatment.

According to the article, the trial's next phase is currently underway.

Read the full article at sclerodermanews.com